Discovery of fully synthetic FKBP12-mTOR molecular glues

Felix Hausch,Robin C.E. Deutscher,Christian Meyners,Maximilian L. Repity,Wisely Oki Sugiarto,Jürgen Kolos,Tim Heymann,Thomas M. Geiger,Stefan Knapp,Frederik Lermyte,Edvaldo Maciel

DOI: https://doi.org/10.26434/chemrxiv-2023-4vb0m-v2

2024-07-02

Abstract:Molecular glues are a class of drug modalities with the potential to engage otherwise undruggable targets. However, the rational discovery of molecular glues for desired targets is a major challenge and most known molecular glues have been discovered by serendipity. Here we present the first fully synthetic FKBP12-mTOR molecular glues, which were discovered from a FKBP-focused, target-unbiased ligand library. Our biochemical screening of >1000 in-house FKBP ligands yielded one hit that induced dimerization of FKBP12 and the FRB domain of mTOR. The crystal structure of the ternary complex revealed that the hit targeted a similar surface on FRB domain compared to natural product rapamycin but with a radically different interaction pattern. Structure-guided optimization improved potency 500-fold and led to compounds, which initiate FKBP12-FRB complex formation in cells. Our results show that molecular glues targeting flat surfaces can be discovered by focused screening and support the use of FKBP12 as a versatile presenter protein for molecular glues.

Chemistry

What problem does this paper attempt to address?

This paper mainly discusses the discovery method of a novel fully synthetic FKBP12-mTOR molecular glue. Molecular glue is a type of drug that can target traditional hard-to-drug targets. The research team discovered a molecular glue that induces dimerization of FKBP12 and the FRB domain of mTOR through high-throughput fluorescence resonance energy transfer (HTRF) screening experiments, among over 1000 compounds. They optimized the screening conditions to detect weakly active compounds as well.

Among the initial screening, compound 7 showed the ability to form ternary complexes and was validated in subsequent experiments such as fluorescence polarization, photocrosslinking, and mass spectrometry. Through crystal structure analysis, researchers found that compound 7 binds to FKBP12 and FRB differently from the natural product rapamycin, but they both act on similar surface areas.

Through structure-guided optimization, they increased the potency of compound 7 by about 500 times, enabling it to initiate the formation of the FKBP12-FRB complex inside cells. The paper points out that this discovery suggests that targeted screening can uncover molecular glues for flat protein surfaces, and FKBP12 may be a multifunctional presenter protein.

In addition, the study emphasizes the importance of high concentrations of target proteins in identifying weakly active molecular glues and proposes a strategy to use weak molecular glues as starting points for rational design to obtain more efficient ones. Finally, the paper discusses that molecular glues may not be as rare as originally thought and proposes several key points for the discovery and optimization of molecular glues, including selecting appropriate presenter proteins, using high concentrations of compounds and target proteins, and utilizing crystal structures for optimization.